Your browser doesn't support javascript.
Use of ivermectin in patients with covid-19: A narrative review
COVID-19 SARS-CoV-2 ivermectin nuclear import pharmacokinetics replication inhibitor General & Internal Medicine ; 2020(Revista Del Cuerpo Medico Del Hospital Nacional Almanzor Aguinaga Asenjo)
Article in Spanish | WHO COVID | ID: covidwho-1262752
ABSTRACT
Introduction. Towards the end of the last month of 2019, a new highly contagious coronavirus was identified in China causing the start of a new pandemic. Millions of infected people and thousands of deaths are the result of SARS-CoV-2 infection;different therapeutic strategies have been proposed for its treatment, one of them has been ivermectin, causing discrepancies in the medical community regarding its use. We set out to review the available scientific evidence on the use of ivermectin in the context of IDVC-19 in humans. A literature search was conducted on the following databases Pub Med, Web of Science, Cochrane, Clinical Trials, and ISRCCTN using search expressions that include the following terms ivermectin, antiviral, virus, covid-19 and/or SARS-CoV-2. There is no scientific evidence to support the use of ivermectin as a treatment and/or prophylaxis for SARS-CoV-2 infection.
Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Prognostic study / Reviews Language: Spanish Journal: COVID-19 SARS-CoV-2 ivermectin nuclear import pharmacokinetics replication inhibitor General & Internal Medicine Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Prognostic study / Reviews Language: Spanish Journal: COVID-19 SARS-CoV-2 ivermectin nuclear import pharmacokinetics replication inhibitor General & Internal Medicine Document Type: Article